• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Choueiri, T
    Larkin, J
    Oya, M
    Thistlethwaite, Fiona C
    Martignoni, M
    Nathan, P
    Powles, T
    McDermott, D
    Robbins, P
    Chism, D
    Cho, D
    Atkins, M
    Gordon, M
    Gupta, S
    Uemura, H
    Tomita, Y
    Compagnoni, A
    Fowst, C
    di Pietro, A
    Rini, B
    Show allShow less
    Affiliation
    Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA
    Issue Date
    2018-04
    
    Metadata
    Show full item record
    Abstract
    The combination of an immune checkpoint inhibitor and a VEGF pathway inhibitor to treat patients with advanced renal-cell carcinoma might increase the clinical benefit of these drugs compared with their use alone. Here, we report preliminary results for the combination of avelumab, an IgG1 monoclonal antibody against the programmed cell death protein ligand PD-L1, and axitinib, a VEGF receptor inhibitor approved for second-line treatment of advanced renal-cell carcinoma, in treatment-naive patients with advanced renal-cell carcinoma.
    Citation
    Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. 2018, 19(4): 451-460 Lancet Oncol
    Journal
    The Lancet Oncology
    URI
    http://hdl.handle.net/10541/620906
    DOI
    10.1016/S1470-2045(18)30107-4
    PubMed ID
    29530667
    Type
    Article
    Language
    en
    ISSN
    1474-5488
    ae974a485f413a2113503eed53cd6c53
    10.1016/S1470-2045(18)30107-4
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.